Arrowhead制药 ARWR 深 沪
已收盘 12-19 16:00:00 美东时间
68.08
+1.610
+2.42%
华盛通- 最 高72.36
- 今 开66.52
- 成交量 132.62万股
- 最 低 43.72
- 昨 收 66.47
- 总市值 72.16亿
- 52周最高 72.36
- 市盈率 静 --
- 换手率 1.25%
- 52周最低 9.57
- 委 比 99.26%
- 总股本 1.06亿
- 历史最高 93.66
- 量 比 0.65
- 振 幅 43.09%
- 历史最低 1.10
- 每 手 1
- 风险率 13.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
12-01 20:29
Gold Gains Over 1%; Nutanix Shares Fall After Q1 Results
U.S. stocks traded higher midway through trading, with the Dow Jones index gain...
11-27 01:16
Arrowhead Pharmaceuticals Earns $200M Milestone Payment From Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone was earned when Arrowhead achieved the second
11-24 20:31
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.
11-19 02:07
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.
03-11 02:02
Arrowhead Pharmaceuticals Files for Phase 1/2a Trial of New Obesity Treatment, ARO-INHBE
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi)
2024-09-23 19:31
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
2024-09-05 19:04
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday
09:13 AM EDT, 09/03/2024 (MT Newswires) -- Health care stocks were leaning lower pre-bell Tuesday with the Health Care Select Sector SPDR Fund (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) recently declining by 0.8%. Vaxcyte (PCVX) shares rose past 31% after it announced plans to launch by...
2024-09-03 21:13
Arrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint
05:15 AM EDT, 09/03/2024 (MT Newswires) -- Arrowhead Pharmaceuticals (ARWR) said Monday a phase 3 study of investigational plozasiran in patients with familial chylomicronemia syndrome met its primary endpoint and all multiplicity-controlled key secondary endpoints. Familial chylomicronemia syndrome...
2024-09-03 17:15
Arrowhead's Plozasiran Meets All Primary and Secondary Endpoints in Phase 3 Study, To Seek FDA Approval
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no approved treatments in the U.S. PALISADE successfully...
2024-09-03 15:09
